Exclusion criteria: <br>1) Presence of a bacterial skin infection which, due to general criteria like severity or depth of the infection, cannot be treated adequately with topical antibiotics alone<br>2) Presence of any of the following skin conditions in the treatment area: viral infections (e.g. herpes simplex, herpes zoster), dermatomycosis, lues or tuberculosis of the skin, inoculation reactions, rosacea or rosacea-like dermatitis<br>3) Necessity of application of the study medication in the area around the eyes<br>4) Necessity of application of the study medication in the area around the ears<br>5) Necessity of application of the study medication near mucous membranes<br>6) Systemic therapy with antibiotics within the last 4 weeks before study inclusion<br>7) Systemic therapy with immunosuppressants or corticoids or medication with neuromuscular blocking effect within the last 2 weeks before study inclusion<br>8) Local treatment in the test area within the last week before study inclusion<br>9) Known intolerance or hypersensitivity against gentamicin or other aminoglycosids, betamethasone or other glucocorticoids, or any of the other ingredients in the study medications<br>10) Advanced renal insufficiency<br>11) Concomitant diseases like e.g. Myasthenia gravis, Parkinson or other neuromuscular disorders<br>12) Other severe acute or chronic concomitant disease with severe impairment of the general condition<br>13) Other concomitant diseases which may - taking the present knowledge into account - influence the parameters evaluated in the study in a way that an objective evaluation would be impossible<br>14) Necessity for a concomitant medication with neuromuscular blocking effect, e.g. benzodiazepines, or other central or peripheral muscle relaxants<br>15) Other concomitant medication which may - taking the present knowledge into account - influence the methods of measurement used in this study or the resulting data<br>16) Reasonable doubt concerning the co-operation of the patient<br>17) Participation in another clinical study within the last 30 days prior to inclusion in this study<br>18) Participation in this study at an earlier date<br>19) Women with existing or intended pregnancy or during lactation<br><br>